Home
Online Advanced Release
Current Issue
Online-only Articles
Back Issues
Product News
About the Journal
Advertising Info
Contact Us
Article Reprints
Article Submission
Buy a Book
Terms and Conditions
Careers at SLACK Inc.
ISIE
 
  e-contents - sign up today
  Subscribe to this Journal
Get daily Ophthalmic news at the OSN SuperSite

Curbside Consultation in Retina

Clinical Science

Anatomic and Visual Outcomes of Vitrectomy for Lamellar Macular Holes

Ophthalmic Surgery, Lasers and Imaging   Vol. 41   No. 4   July/August 2010
See the Full text
Andre J. Witkin, MD; Leonardo C. Castro, MD; Elias Reichel, MD; Adam H. Rogers, MD; Caroline R. Baumal, MD and Jay S. Duker, MD

Share/Save/Bookmark

 

BACKGROUND AND OBJECTIVE

To assess anatomic and visual outcomes after pars plana vitrectomy for lamellar macular holes.

PATIENTS AND METHODS

Charts of 746 patients who had vitrectomy surgery with membrane peel were reviewed. Preoperative diagnosis of lamellar macular hole was based on optical coherence tomography (OCT) appearance; 16 eyes of 16 patients met the inclusion criteria.

RESULTS

Mean acuity was 20/158 preoperatively and 20/118 postoperatively (P = .408). Central macular thickness was 377.06 µm preoperatively and 245.7 µm postoperatively (P = .002). Two eyes (13%) developed full-thickness macular holes postoperatively. Six eyes (38%) continued to have a lamellar macular defect on OCT postoperatively.

CONCLUSION

Despite postoperative anatomic improvement in many patients and an overall decrease in foveal thickness on OCT, this retrospective series suggests that vitrectomy for lamellar holes may not improve visual acuity.

[Ophthalmic Surg Lasers Imaging 2010;41:418-424.]

AUTHORS

From Tufts Medical Center, Department of Ophthalmology, Boston, Massachusetts.

Originally submitted August 23, 2009. Accepted for publication January 28, 2010. Posted online April 29, 2010.

Presented at the annual meeting of the Association for Research in Vision and Ophthalmology, May 3-7, 2009, Fort Lauderdale, Florida.

Supported in part by an RPB Challenge grant to the New England Eye Center/Department of Ophthalmology, Tufts University School of Medicine and in part by a departmental grant from Massachusetts Lions.

Dr. Duker is a consultant for Alcon, Genentech, and Ophthotech, is a scientific advisor for Paloma Pharmaceuticals, and receives research support from OptiVue and Carl Zeiss Meditec. Drs. Witkin, Castro, Reichel, Rogers, and Baumal have no financial or proprietary interest in the materials presented herein.

Dr. Duker did not participate in the editorial review of this manuscript.

Address correspondence to Andre J. Witkin, MD, Tufts Medical Center, 800 Washington Street, Box 450, Boston, MA 02111.

doi: 10.3928/15428877-20100426-04

See the Full text